CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in ...
U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback